Lucia Palombi1, Paolo Marchetti2, Maurizio Salvati3, Mattia Falchetto Osti4, Luigi Frati3, Alessandro Frati3. 1. Department of Neurological Sciences-Neurosurgery, Faculty of Medicine, La Sapienza University of Rome, Rome, Italy luciapalombi@gmail.com. 2. Department of Oncology, Faculty of Medicine and Psychology, La Sapienza University of Rome, Rome, Italy. 3. IRCCS INM Neuromed, Pozzilli, Italy. 4. Department of Radiation Oncology, Faculty of Medicine and Psychology, La Sapienza University of Rome, Rome, Italy.
Abstract
BACKGROUND: Patients affected by glioblastoma often develop cerebral oedema as a life-threatening complication. Although there is no approved pharmacological intervention, such cerebral oedema is usually treated with dexamethasone. Dexamethasone has been shown in experimental studies to reduce cerebral oedema with only few mineralocorticoid side-effects. The goal of our study was to examine its efficacy in reducing the emergence of neurological deficits during the Stupp protocol. PATIENTS AND METHODS: We studied a retrospective cohort of 459 patients, assigned in controlled groups: in group A, patients received radiochemotherapy followed by adjuvant chemotherapy; in group B, patients received an equivalent combined treatment with dexamethasone. RESULTS: The frequency of neurological symptoms was significantly lower in dexamethasone-treated patients. CONCLUSION: Early diagnosis and prevention of cerebral oedema are important because functional consequences can be anticipated with an appropriate medical treatment. Thus, our study reveals that dexamethasone acts to prevent the appearance of neurological symptoms in patients with brain tumour. Copyright
BACKGROUND:Patients affected by glioblastoma often develop cerebral oedema as a life-threatening complication. Although there is no approved pharmacological intervention, such cerebral oedema is usually treated with dexamethasone. Dexamethasone has been shown in experimental studies to reduce cerebral oedema with only few mineralocorticoid side-effects. The goal of our study was to examine its efficacy in reducing the emergence of neurological deficits during the Stupp protocol. PATIENTS AND METHODS: We studied a retrospective cohort of 459 patients, assigned in controlled groups: in group A, patients received radiochemotherapy followed by adjuvant chemotherapy; in group B, patients received an equivalent combined treatment with dexamethasone. RESULTS: The frequency of neurological symptoms was significantly lower in dexamethasone-treated patients. CONCLUSION: Early diagnosis and prevention of cerebral oedema are important because functional consequences can be anticipated with an appropriate medical treatment. Thus, our study reveals that dexamethasone acts to prevent the appearance of neurological symptoms in patients with brain tumour. Copyright
Authors: Charissa A C Jessurun; Alexander F C Hulsbergen; Anouk E de Wit; Ishaan A Tewarie; Tom J Snijders; Joost J C Verhoeff; John G Phillips; David A Reardon; Rania A Mekary; Marike L D Broekman Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 12.300
Authors: Marciana N Duma; Nadja I Oszfolk; Tobias Boeckh-Behrens; Markus Oechsner; Claus Zimmer; Bernhard Meyer; Paul T Pfluger; Stephanie E Combs Journal: Radiat Oncol Date: 2019-06-07 Impact factor: 3.481
Authors: Bangxing Hong; Kamaldeen Muili; Chelsea Bolyard; Luke Russell; Tae Jin Lee; Yeshavanth Banasavadi-Siddegowda; Ji Young Yoo; Yuanqing Yan; Leomar Y Ballester; Kurt H Bockhorst; Balveen Kaur Journal: Mol Ther Oncolytics Date: 2018-12-06 Impact factor: 7.200
Authors: Dirk Rades; Jaspar Witteler; Denise Olbrich; Peter Trillenberg; Steven E Schild; Soeren Tvilsted; Troels W Kjaer Journal: BMC Cancer Date: 2021-04-09 Impact factor: 4.430